Navigation Links
TWi Biotechnology Inc. Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients
Date:12/24/2015

TAIPEI, Taiwan, Dec. 24, 2015 /PRNewswire/ -- TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor.

The interim analysis is for the first enrollment cohort (18 per arm completing Week 8), if the number of subjects in the AC-201 CR arm achieving the clinical target of sUA <6.0 mg/dL at Week 8 is at least 2 greater than the number in the placebo arm, then the remaining subjects  will be enrolled in the second cohort; if not, enrollment will be stopped. Based on the report, the responders in AC-201 CR arm is at least 2 greater than the number in the placebo arm. In addition to producing the efficacy of AC-201 CR in gout patients, there have been no serious adverse events reported to date and AC-201 CR was generally safe and well tolerated in the study patients. Therefore, TWIB is able to continue to enroll second cohort subjects and complete this clinical trial in the end of 2016.

"We are encouraged to see the potential efficacy of AC-201 CR in the Phase 2 proof-of-concept study results to date," said Dr. Calvin C. Chen, President and CEO of TWIB. "Current evidence of AC-201 CR efficacy and the preliminary results for tolerance support the potential of AC-201 CR as a dual uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and the prevention of gout flares when combining with xanthine oxidase inhibitor. I am very pleased with the interim data as it indicates AC-201 CR may increase the successful rate of the treatment of gout without increase or even decrease the flare rate. The poor compliance of the urate lowering therapy due to frequent gout flares at the initiation and low treatment successful rate offered by existing therapies are the major unmet needs for the management of sUA and gout."

About the Study

The ongoing Phase 2a study (study code: AC-201-GOU-002) is an randomized, double-blind, placebo-controlled, multicenter study. This study is designed to test the urate-lowering effects, safety and tolerability of AC-201 controlled-release tablets (vs.placebo) in an initial dosing period as a monotherapy, followed by addition of febuxostat to test the efficacy and safety of the combination. At up to a maximum of 14 clinical sites in Taiwan, the study aims to enroll 140 eligible subjects, who are confirmed with gout, and who will be randomized in a 1:1 allocation ratio to either AC-201 CR or Placebo over a with a 12-week treatment period and a 4-week follow-up period.

The primary efficacy endpoint is the proportion of subjects achieving serum uric acid concentration <6.0 mg/dL at Week 8. The major secondary efficacy endpoints are proportion of subjects achieving serum uric acid concentration <6.0 mg/dL or <5.0 mg/dL at each visit; number of gout flares per subject during each period and overall.

About Hyperuricemia and Gout

Gout is a medical condition usually characterized by recurrent attacks of acute inflammatory arthritis -- a red, tender, warm, swollen joint caused by an inflammatory response to uric acid crystals deposited in joints and soft tissues as a result of elevated levels of uric acid in the blood (hyperuricemia). Urate crystals in joints can trigger acute arthritic flares, chronic destructive arthropathy, and formation of tophi. According to the U.S. National Health and Nutrition Examination Survey (NHANES) study, the prevalence of gout among US adults in 2007-2008 was 3.9% (8.3 million individuals).

About AC-201/ AC-201 CR

AC-201 is a first-in-class, orally available small molecule which has shown the dual abilities to inhibit URAT1 as well as the production and activity of caspase-1 and the cytokine Interleukin-1Beta (IL-1Beta) through the inhibition of the assembly of the NLRP3 inflammasome. Inhibition of the NLRP3 inflammasome associated signaling pathway and IL-1Beta has been demonstrated to be effective in treating a variety of diseases including arthritis, gout, and diabetes mellitus (DM). The active ingredient of AC-201 has been approved for treating patients with chronic rheumatic diseases in France and subsequently in other EU and Middle Eastern countries such as Spain and Italy since mid-1990. AC-201 CR is the controlled release oral formulation of AC-201.

TWi Biotechnology holds two US INDs for AC-201 -- one for controlling blood glucose in patients with type II diabetes and the other for treating gout in patients under taking urate-lowering therapy. In addition to the good safety record of its active ingredient used in treating another chronic disease, AC-201 has undergone testing in several human clinical trials including 3 phase II trials with up to 6 months treatment period with a satisfactory safety profile demonstrated.

About TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a subsidiary of TWi Pharmaceuticals, Inc., is a leading clinical stage biopharmaceutical company based in Taipei, Taiwan, specializing in the development of innovative new drugs for unmet medical needs, especially in the diseases associated with innate immunity. The company is building its product pipeline through in-licensing and internal research. TWi Biotechnology's product development pipeline includes two drug candidates for treating type II diabetes, arthritis, gout, and immunodermatology diseases. TWi Biotechnology holds US and Taiwan orphan drug designations for AC-203 for Epidermolysis Bullosa treatment as well as two US INDs for the oral dosage form of the molecule for type 2 diabetes and gout treatment.

Contact :
Weishu Lu 
Tel: +886-2-2657-1788 #300
email: weishu.lu@twibiotech.com

 


'/>"/>
SOURCE TWi Biotechnology, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Blueprint Medicines Added to NASDAQ Biotechnology Index
2. Egalet Added to NASDAQ Biotechnology Index
3. TWi Biotechnology Inc. Announces Development and Commercialization Agreement and Collaboration with Castle Creek Pharmaceuticals, LLC
4. TaiGen Biotechnology Launches Taigexyn(R) in Taiwan
5. Teligent, Inc. Added To NASDAQ Biotechnology Index (NBI)
6. Construction Begins at Genovate Biotechnologys Insulin Ecological Industrial Park in Chinas Changzhou National Hi-tech District
7. Baustart im Insulin Ecological Industrial Park von Genovate Biotechnology in Chinas Changzhou National Hi-Tech District
8. Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis
9. Global Pharmaceutical and Biotechnology Industry Boosts Confidence for Investors as the Market Expands
10. Global Aptamers (DNA, RNA, XNA) Market 2015-2020 - End-User Analysis: Academic Research Institutes, Biotechnology & Pharmaceutical Companies & CRO
11. Eli Lilly and Company Announces Expansion of San Diego Biotechnology Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Rosen Law Firm, ... of a class action lawsuit on behalf of purchasers ... KTOV ) pursuant and/or traceable to Kitov,s initial public ... and/or on the open market from November 20, 2015 ... Period"). The lawsuit seeks to recover damages for Kitov ...
(Date:3/28/2017)... 2017 Summary ... as a Key Component of Multichannel Marketing" provides ... landscape in the digital age. While the ... medical advancements, it has been much slower to ... on traditional channels and methods. However, the decreasing ...
(Date:3/28/2017)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... and year ended December 31, 2016. ... Orexigen, beginning with the re-acquisition of the rights to ... team at Orexigen demonstrated remarkable focus, executing on a ... our Company while rewarding us full control of our ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a ... the finalization of the company’s executive management team with prominent executives from both inside ... Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty ...
(Date:3/29/2017)... CA (PRWEB) , ... March 29, 2017 , ... Hamlin ... Northridge , is now offering laser dental treatments. Dental lasers are safe and effective ... dentistry expands patients’ options and can improve the overall quality of care. , Dr. ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 ... the only option for on-premises installation of its Help System for SharePoint was at ... the system into the entire tenant. , The company recently released a modified ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors is ... his extensive knowledge of appraisals, property values, ad valorem taxation, and government policy ... industry for more than 40 years. , “Ruel is a great addition to ...
Breaking Medicine News(10 mins):